Response Biomedical Corp (RBM) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
1781 - 75TH AVENUE W. VANCOUVER, BC V6P6P2 |
| State of Incorp. | BC |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8734 - Testing Laboratories (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2016 Q3 | 6/30/2016 Q2 | 3/31/2016 Q1 | 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,580 | 1,021 | 2,511 | 2,878 | 1,586 | 1,439 | |||
| Cash and cash equivalent | 1,580 | 1,021 | 2,511 | 2,878 | 1,586 | 1,439 | |||
| Receivables | 521 | 710 | 566 | 557 | 2,015 | 1,872 | |||
| Inventory, net of allowances, customer advances and progress billings | 2,195 | 2,142 | 1,819 | 2,102 | 2,725 | 2,499 | |||
| Inventory | 2,195 | 2,142 | 1,819 | 2,102 | 2,725 | 2,499 | |||
| Deferred costs | 90 | 57 | 66 | 77 | |||||
| Other undisclosed current assets | 667 | 109 | 134 | 145 | 167 | 301 | |||
| Total current assets: | 4,963 | 3,982 | 5,120 | 5,739 | 6,559 | 6,188 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 5,330 | 5,573 | 5,689 | 5,907 | 6,151 | 6,392 | |||
| Prepaid expense | 93 | 93 | 93 | 93 | 93 | 93 | |||
| Restricted cash and investments | 317 | 317 | 901 | 901 | 901 | 901 | |||
| Deferred costs | 3 | 9 | 18 | 30 | |||||
| Total noncurrent assets: | 5,740 | 5,983 | 6,686 | 6,910 | 7,163 | 7,416 | |||
| TOTAL ASSETS: | 10,703 | 9,965 | 11,806 | 12,649 | 13,722 | 13,604 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 3,962 | 3,755 | 3,466 | 3,838 | 5,280 | 4,834 | |||
| Accounts payable | 3,793 | 3,586 | 3,297 | 3,669 | 5,111 | 4,665 | |||
| Accrued liabilities | 169 | 169 | 169 | 169 | 169 | 169 | |||
| Debt | 748 | 814 | 868 | 840 | 783 | 796 | |||
| Derivative instruments and hedges, liabilities | 964 | 742 | 301 | 454 | 1,344 | 1,194 | |||
| Deferred revenue and credits | 1,530 | 192 | 1,311 | 1,588 | 867 | 1,083 | |||
| Other undisclosed current liabilities | 515 | 481 | 489 | 468 | 448 | 428 | |||
| Total current liabilities: | 7,719 | 5,984 | 6,435 | 7,188 | 8,722 | 8,335 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation, including: | 4,415 | 4,556 | 4,694 | 4,828 | 4,958 | 5,085 | |||
| Long-term debt, excluding current maturities | 4,415 | 136 | 360 | 555 | 706 | 910 | |||
| Other undisclosed long-term debt and lease obligation | 4,420 | 4,334 | 4,273 | 4,252 | 4,175 | ||||
| Other undisclosed noncurrent liabilities | 943 | 1,121 | 1,388 | 1,625 | 1,818 | 2,064 | |||
| Total noncurrent liabilities: | 5,358 | 5,677 | 6,082 | 6,453 | 6,776 | 7,149 | |||
| Total liabilities: | 13,077 | 11,661 | 12,517 | 13,641 | 15,498 | 15,484 | |||
| Equity | |||||||||
| Equity, attributable to parent | (2,374) | (1,696) | (711) | (992) | (1,776) | (1,880) | |||
| Common stock | 105,010 | 104,314 | 104,314 | 104,314 | 104,314 | 104,270 | |||
| Additional paid in capital | 15,596 | 15,649 | 15,384 | 15,326 | 15,271 | 15,209 | |||
| Accumulated deficit | (122,980) | (121,659) | (120,409) | (120,632) | (121,361) | (121,359) | |||
| Total equity: | (2,374) | (1,696) | (711) | (992) | (1,776) | (1,880) | |||
| TOTAL LIABILITIES AND EQUITY: | 10,703 | 9,965 | 11,806 | 12,649 | 13,722 | 13,604 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2016 Q3 | 6/30/2016 Q2 | 3/31/2016 Q1 | 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 1,321 | 2,204 | 4,084 | 3,528 | 4,266 | 3,540 | ||
| Cost of revenue (Cost of Product and Service Sold) | (799) | (1,177) | (1,424) | (1,491) | (2,167) | (2,243) | ||
| Other undisclosed gross profit | (196) | 68 | 47 | 67 | ||||
| Gross profit: | 522 | 1,027 | 2,464 | 2,105 | 2,146 | 1,364 | ||
| Operating expenses | (1,439) | (1,819) | (1,996) | (1,875) | (1,771) | (2,152) | ||
| Operating income (loss): | (917) | (792) | 468 | 230 | 375 | (788) | ||
| Nonoperating income (expense) | (405) | (458) | (920) | 714 | (152) | (77) | ||
| Investment income, nonoperating | (223) | (441) | 892 | (148) | 58 | |||
| Gain (loss), foreign currency transaction, before tax | (3) | 202 | (166) | (21) | (113) | |||
| Other nonoperating income (expense) | (2) | (28) | (12) | 17 | (22) | |||
| Interest and debt expense | (177) | (191) | (203) | (215) | (225) | (235) | ||
| Income (loss) from continuing operations: | (1,499) | (1,441) | (655) | 729 | (2) | (1,100) | ||
| Income (loss) before gain (loss) on sale of properties: | (1,499) | (1,441) | (655) | 729 | (2) | (1,100) | ||
| Net income (loss): | (1,499) | (1,441) | (655) | 729 | (2) | (1,100) | ||
| Other undisclosed net income attributable to parent | 177 | 191 | 878 | |||||
| Net income (loss) available to common stockholders, diluted: | (1,322) | (1,250) | 223 | 729 | (2) | (1,100) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2016 Q3 | 6/30/2016 Q2 | 3/31/2016 Q1 | 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,499) | (1,441) | (655) | 729 | (2) | (1,100) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,499) | (1,441) | (655) | 729 | (2) | (1,100) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.